Annovis Bio CEO to Present at H.C. Wainwright Global Investment Conference

Annovis Bio Inc. (NYSE: ANVS) has announced that CEO Maria Maccecchini, Ph.D., will present at the H.C. Wainwright 27th Annual Global Investment Conference scheduled for September 8-10, 2025, at the Lotte New York Palace Hotel in New York City. This presentation represents a significant opportunity for the company to showcase its advancements in neurodegenerative disease research and development to a global investment audience.

The conference participation underscores Annovis Bio's ongoing commitment to addressing neurodegeneration in critical conditions such as Alzheimer's disease (AD) and Parkinson's disease (PD). The company's presence at this prestigious event demonstrates its progress in developing innovative therapeutic approaches that aim to improve patient outcomes and enhance quality of life for those affected by these debilitating neurological disorders.

Investors and industry stakeholders can access the full press release detailing the conference presentation through the company's official communication channels at https://ibn.fm/bX1aJ. This presentation comes at a crucial time for the biotechnology sector, particularly for companies focused on neurodegenerative diseases, which represent one of the most challenging and underserved areas in modern medicine.

The H.C. Wainwright Global Investment Conference serves as a premier platform for emerging and established biotechnology companies to connect with institutional investors, analysts, and industry partners. Annovis Bio's participation in this event highlights the company's growing visibility within the investment community and its potential to make significant contributions to the treatment of neurodegenerative conditions.

For ongoing updates and comprehensive information about Annovis Bio's research initiatives and corporate developments, interested parties can monitor the company's official newsroom available at https://ibn.fm/ANVS. The conference presentation will likely provide valuable insights into the company's strategic direction, clinical progress, and future milestones in the competitive neurodegenerative disease therapeutic landscape.